74%
of retail investor accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
74%
of retail investor accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Krystal Biotech Inc
Closed
SectorHealthcare
264.15 1.2
Overview
Share price change
24h
Min
254.9
Max
264.34
Income | -28M 51M |
|---|---|
Sales | 9.3M 107M |
P/E Sector Avg | 38.331 66.418 |
Profit margin | 47.99 |
Employees | 295 |
EBITDA | -10M 40M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +24.14% upside |
Next Earnings | 5 May 2026 |
|---|
Market Cap | -363M 7.7B |
|---|---|
Previous open | 262.95 |
Previous close | 264.15 |
News Sentiment
By Acuity
43%
57%
133 / 349 Healthcare
Technical Score
By Trading Central
Confidence
Very Strong Bearish Evidence
Krystal Biotech Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Krystal Biotech Inc Forecast
Price Target
By TipRanks
24.14% upside
12 Months Forecast
Average 325 USD 24.14%
High 371 USD
Low 284 USD
Based on 12 Wall Street analysts offering 12 month price targets forKrystal Biotech Inc - Dist in the last 3 months.
Sentiment
By Acuity
133 / 349 Healthcare
News Sentiment
Bullish Evidence
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Krystal Biotech Inc
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Live chat